Skip to Content
MilliporeSigma
All Photos(1)

Documents

05-321MG

Sigma-Aldrich

Anti-Phosphotyrosine Antibody, clone 4G10®

clone 4G10®, Upstate®, from mouse

Synonym(s):

Clone 4G10 Anti-Phosphotyrosine, Phosphotyrosine Detection Antibody

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified from hybridoma cell culture

antibody product type

primary antibodies

clone

4G10®, monoclonal

species reactivity (predicted by homology)

all

manufacturer/tradename

Upstate®

technique(s)

immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG2bκ

shipped in

wet ice

target post-translational modification

phosphorylation (pTyr)

Application

Anti-Phosphotyrosine Antibody, clone 4G10 detects level of Phosphotyrosine & has been published & validated for use in IP & WB.

Quality

Routinely evaluated on EGF-treated human A431 carcinoma cells.

Western Blot Analysis:
0.5-2 μg/mL of this lot detected tyrosine-phosphorylated proteins in a modified RIPA lysate from EGF-treated human A431 carcinoma cells (Cohen, B., 1990; Druker, B. J., 1989; Kanakura, Y., 1991).

Target description

Dependent upon the molecular weight of the tyrosine phosphorylated protein being detected.

Physical form

Format: Purified
Purified mouse monoclonal IgG2bκ in buffer containing PBS, pH 7.4. Liquid at 2-8ºC.
IgG2bκ mouse monoclonal antibody produced in vitro by mouse-mouse hybridoma 4G10 (FOX-NY [NS-1 derivative] myeloma x spleen cells).

Analysis Note

Control
Positive Antigen Control: Catalog #12-302, EGF-stimulated A431 cell lysate. Add 2.5µL of 2-mercaptoethanol/100µL of lysate and boil for 5 minutes to reduce the preparation. Load 20µg of reduced lysate per lane for minigels.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

4G10 is a registered trademark of Upstate Group, Inc.
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

12 - Non Combustible Liquids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Zhi Liu et al.
The Journal of biological chemistry, 290(12), 7535-7562 (2015-01-15)
Producing pure and well behaved bispecific antibodies (bsAbs) on a large scale for preclinical and clinical testing is a challenging task. Here, we describe a new strategy for making monovalent bispecific heterodimeric IgG antibodies in mammalian cells. We applied an
Hoang Thanh Chi et al.
Biomedical reports, 19(1), 47-47 (2023-06-29)
ETS variant transcription factor 6 (ETV6)-neurotrophic receptor tyrosine kinase 3 (NTRK3) (EN) fusions are typically found in rare diseases, such as primary renal fibrosarcoma (only six cases have been reported), secretory carcinoma of the breast and salivary gland (1 case)
Xin A Zhang et al.
The Journal of biological chemistry, 278(29), 27319-27328 (2003-05-10)
KAI1/CD82 protein is a member of the tetraspanin superfamily and has been rediscovered as a cancer metastasis suppressor. The mechanism of KAI1/CD82-mediated suppression of cancer metastasis remains to be established. In this study, we found that migration of the metastatic
Hui Guo et al.
Acta pharmacologica Sinica, 39(3), 425-437 (2017-11-10)
STAT1 and STAT3 are two important members of the STAT (signal transducers and activators of transcription) protein family and play opposing roles in regulating cancer cell growth. Suppressing STAT3 and/or enhancing STAT1 signaling are considered to be attractive anticancer strategies.
Yongsheng Ruan et al.
Experimental and therapeutic medicine, 23(1), 47-47 (2021-12-23)
Treatment of resistant or recurrent acute lymphoblastic leukemia (ALL) remains a challenge. It was previously demonstrated that the adhesion molecule integrin α4, referred to hereafter as α4, mediates the cell adhesion-mediated drug resistance (CAM-DR) of B-cell ALL by binding to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service